BioSpace News Archive

Inspire Medical Systems, Inc. and Lovell® Government Services, Inc. announced that they have partnered to provide the Inspire therapy system to Federal Healthcare Systems.

Vivera is pleased to welcome Lea Ramirez to the Company’s Advisory Board.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria® Panel to include the detection of Acinetobacter baumannii.

Vivacelle Bio, Inc., a privately held company focused on the development of improved treatments for septic shock, today announced early results from its Phase IIa clinical trial of VBI-S in septic shock patients.

NovAccess Global Inc., a biomedical company developing novel immunotherapies for brain tumor patients, announced the availability of its initial installment in a series of interviews with its corporate leadership on a monthly basis for the next four months, with additional sessions to be made available as company developments arise.

HealthTrackRx, the nation’s premier PCR-based diagnostic testing lab, announced it would present findings from a study titled A comparative analysis of the detection of UTI pathogens via culture method and the Open Array ®-nanofluidic real-time PCR method at IDWeek 2022.

HighTide Therapeutics, Inc., a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, announced the appointment of Daniel Ripley as Senior Vice President of Business Development.

Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI).

Corium, LLC and Gurnet Point Capital announced the acquisition of their manufacturing business and a $100 million equity investment by Webster Equity Partners, a healthcare-focused private equity firm that focuses on applying its expertise in the health care services sector to drive sustainability and long term value.

As part of a 320m SEK investment program in biological therapies, one research project will play a pivotal role in making Sweden a major leader in Advanced Therapeutic Medical Products (ATMPs) by 2030.